Anteris Technologies opened lower at $6.15, compared with its previous close of $6.20. In the last trading session, the stock traded between $5.82 and $6.26. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Anteris Technologies is now worth
$ 104.48
Giving a profit of
$ 4.48 (4.48%)
Invest with $1
Note: Past profits do not guarantee future returns.
Net operating cash outflows reached $22.9 million in Q3FY26, driven by clinical and manufacturing costs. R&D expenses totaled $21.3 million, reflecting scaled manufacturing and PARADIGM trial activities. The PARADIGM Trial expanded into Germany and Australia following new regulatory clearances. Anteris assumed occupancy of the Northcross facility in Minnesota to boost production capacity. Brent Moen was appointed Chief Financial Officer effective September 11, 2026.
2 days ago
20Oct
Anteris secures German regulatory clearance for PARADIGM trial expansion
Anteris Technologies Global Corp received full regulatory clearance from Germany's BfArM for the PARADIGM Trial. The approval allows patient recruitment in Germany, Europe's largest TAVR market, accelerating enrollment. The PARADIGM Trial will enroll approximately 1,000 patients in a 1:1 randomized comparison against commercial valves. Primary endpoints include all-cause mortality, all stroke, and cardiovascular hospitalization at one year.
24 days ago
1Sep
Anteris CEO to present at three major US healthcare conferences
Wayne Paterson to present at Cantor, Wells Fargo, and Morgan Stanley conferences. Sessions scheduled for September 9, 10, and 14, 2026 in New York and Boston. Anteris focuses on DurAVR THV for treating aortic stenosis. ADAPT tissue technology used in over 55,000 patients globally.
2mo ago
12Aug
Anteris Technologies Q2 loss widens, sales miss estimates
Anteris Technologies Global Corp reported a Q2 loss per share of $(0.30), missing analyst estimates of $(0.21), and revenue of $1.009 million, below the $1.500 million consensus. However, both metrics improved significantly year-over-year, with revenue up 63.27%. The financials reflect heavy investment in the PARADIGM Trial and regulatory milestones, including U.S. Medicare coverage eligibility.
